Similar rates of skin improvement at week 100 indicate Skyrizi® (risankizumab) has consistent long-term efficacy in psoriatic arthritis patients.
List view / Grid view
Phase III trial data shows more than half of patients with moderate to severe Crohn's disease treated with risankizumab (Skyrizi®) 360mg achieved clinical remission in a year.
Two Phase III trials have shown that two doses of risankizumab met the primary endpoints in patients with Crohn's disease.
The adaptive ACTIV-5/BET study will test two monoclonal antibody therapies in hospitalised COVID-19 patients to establish if they warrant larger clinical trials.
NICE has issued a recommendation for risankizumab to treat patients with severe plaque psoriasis.